Home › Companies › NTLA

Intellia Therapeutics

NTLA Rare disease Lead: NDA Submitted ★ Read the deep dive → 6 Biotech Distilled articles ↓

Cardiovascular Immunology Gene Therapy

Most recent annual filing: 2026-02-15

Pipeline (5 active programs)

lonvoguran ziclumeran

lonvo-z · NTLA-2002

Gene Therapy Target: KLKB1

Hereditary Angioedema NDA Submitted intravenous

nexiguran ziclumeran

nex-z · NTLA-2001

Gene Therapy Target: TTR

Transthyretin Amyloidosis with Cardiomyopathy Phase 3 intravenous Regeneron
Hereditary Transthyretin Amyloidosis with Polyneuropathy Phase 3 intravenous Regeneron

nexiguran ziclumeran

NTLA-2001 · nex-z

Gene Therapy Target: TTR

ATTR Amyloidosis with Cardiomyopathy Phase 3 intravenous Regeneron Pharmaceuticals
Hereditary ATTR Amyloidosis with Polyneuropathy Phase 3 intravenous Regeneron Pharmaceuticals

Biotech Distilled coverage (6)

2026-06-15 UPDATE: Intellia Therapeutics (NTLA) - The HAELO Receipts Land in NEJM
2026-05-12 UPDATE: Intellia Therapeutics (NTLA) - The MAGNITUDE Hold Quietly Lifted 🔒 Paid
2026-04-30 UPDATE: Intellia Therapeutics (NTLA) - The Offering Priced at $10.75 🔒 Paid
2026-04-28 UPDATE: Intellia Therapeutics (NTLA) - The Code Compiled Clean 🔒 Paid
2026-04-27 UPDATE: Intellia Therapeutics (NTLA) - The Clock Is Set for Monday Morning 🔒 Paid
2026-03-05 Intellia Therapeutics (NTLA) - Scientific Deep Dive for Lead and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.